Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KIT K642E |
Therapy | Imatinib |
Indication/Tumor Type | mucosal melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT K642E | mucosal melanoma | predicted - sensitive | Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) treatment resulted in a best overall response rate of 53.8% (7/13, all partial responses) in patients with mucosal, acral, or chronically sun-damaged skin melanoma harboring KIT activating mutations in exons 11 (n=9), 13 (n=3), and 17 (n=1), including 1 partial response and 1 with stable disease in patients with mucosal melanoma harboring KIT K642E (n=3)(PMID: 23775962; NCT00424515). | 23775962 |
PubMed Id | Reference Title | Details |
---|---|---|
(23775962) | Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. | Full reference... |